Gotta wonder why this potency issue wasn’t addressed BEFORE the 2nd BLA application was presented. I can only assuage that the FDA has been playing a ‘cat & mouse’ game with mesoblast…….throughout the process a lot of virtue signalling about the therapy…head nodding…..everything is ‘reasonable….the welcome mat is out….until the moment of truth arrives for actual approval…..then that welcome mat morphs into a trapdoor that propels you into a myriad of dead end delay pathways.
Gotta wonder why this potency issue wasn’t addressed BEFORE the...
-
- There are more pages in this discussion • 155 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
0.015(0.93%) |
Mkt cap ! $2.082B | |||
| Open | High | Low | Value | Volume |
| $1.63 | $1.67 | $1.61 | $6.975M | 4.265M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 707 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.64 | 7320 | 2 |
View Market Depth
| Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |